

Special Issue

Advances in Colorectal Cancer Survival Analysis

Message from the Guest Editor

Considerable progress has been made in colorectal cancer research in recent times. Identification of high-risk patients, genetic modifications, chemotherapy regimens and immune therapy for tumors are just a few of the recent discoveries. Every patient and every type of cancer is different, and there are differences within the same cancer in the same patient. New prognostic factors have emerged in terms of prevention, diagnosis, treatment and follow-up of patients with colorectal cancer. The understanding of prognostic inference factors will allow an appropriate treatment strategy but also new research directions. Bringing together in this special issue the latest perspectives in the management of colorectal cancer will facilitate a better management of this disease.

Guest Editor

Dr. Bogdan Badic
Centre Hospitalier Universitaire de Brest, Brest, France

Deadline for manuscript submissions

closed (15 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/142668

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)